72 patents
Page 2 of 4
Utility
Triazolones, Tetrazolones, and Imidazolones, or Their Salts, and Pharmaceutical Compositions Comprising the Same
1 Dec 22
The present technology provides triazolones, tetrazolones, and imidazolones, or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof.
Hee Jae TAK, Eun Kyung KIM, Hyok Jun CHO, Cheol Hee LIM
Filed: 21 Apr 22
Utility
Novel Processes for Preparing a Diaminopyrimidine Derivative or Acid Addition Salt Thereof
1 Dec 22
The present invention provides a novel process for preparing a diaminopyrimidine derivative or acid addition salt thereof having an activity as a 5-HT4 receptor agonist.
Ja-Heouk KHOO, Doo-Byung LEE, Jun-Sup LEE, Hyun JU, Woo-Seob SHIN
Filed: 26 Jul 22
Utility
Anti-TIGIT antibodies and uses thereof
22 Nov 22
Kwang-Hoon Lee, June Hyung Lee, Na Rae Lee, Eunjeong Jeong, Young Bong Park, Nakho Chang, Eun-Jung Lee, Ki Hong Kim, Sunghyun Choi, Byung Hyun Choi, Ju Young Park, Moo Young Song, Jong-Seo Lee, Kyu-Tae Kim, Bong-Kook Ko
Filed: 28 Feb 19
Utility
Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same
8 Nov 22
The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof.
Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Su Bin Choi, Dong Hoon Kim, Sol Park, Eun Hye Jung, Hyun Ho Choi, Tae Wang Kim, Mi Kyeong Ju, Na Ry Ha
Filed: 25 Nov 20
Utility
Fusion protein comprising thyrotropin receptor variants and use thereof
25 Oct 22
Disclosed are a fusion protein comprising a thyrotropin receptor (TSHR) fragment and the use thereof.
Moo Young Song, Taejin Yoon, Jung-Sun Lee, Byung Hyun Choi, In Hwan Lim, Man Sil Park, Jin-Hyoung Lee, Hyoung Sig Seo, Hyeon Woo Kang, Sung Ho Kim, Eun Jig Lee, Jin Sook Yoon, Cheol Ryong Ku
Filed: 24 Jul 19
Design
Toothbrush
11 Oct 22
Sung Jin Lee
Filed: 23 Sep 20
Design
Toothbrush
11 Oct 22
Sung Jin Lee
Filed: 23 Sep 20
Utility
Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
27 Sep 22
The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yppyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same.
Sang Ho Oh, Jong Gyun Kim, Se-Woong Oh, Tae Dong Han, Soo Yong Chung, Seong Ran Lee, Kyeong Bae Kim, Young Sung Lee, Woo Seob Shin, Hyun Ju, Jeong Ki Kang, Su Min Park, Dong Kyun Kim
Filed: 18 Apr 18
Utility
Process For Preparing Aminopyrimidine Derivatives
8 Sep 22
The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors.
Sang-Ho Oh, Ja-Heouk Khoo, Jong-Chul Lim, Seong-Ran Lee, Hyun Ju, Woo-Seob Shin, Dae-Gyu Park, Su-Min Park, Yoon-Ah Hwang
Filed: 25 Mar 22
Utility
Processes for preparing a diaminopyrimidine derivative or acid addition salt thereof
6 Sep 22
Provided are a novel process for preparing a diaminopyrimidine derivative or acid addition salt thereof having an activity as a 5-HT4 receptor agonist, crystalline forms of a hydrochloride of the diaminopyrimidine derivative, and processes for preparing the same.
Ja-Heouk Khoo, Doo-Byung Lee, Jun-Sup Lee, Hyun Ju, Woo-Seob Shin
Filed: 16 May 19
Utility
Processes for preparing (E)-(2-(chloromethyl)-3-fluoroallyl) carbamate compounds
17 May 22
The present technology provides a process for selectively preparing an (E)-(2-(chloromethyl)-3-fluoroallyl)carbamate compound by refluxing an (E/Z)-(2-(chloromethyl)-3-fluoroallyl)carbamate compound in an organic solvent, followed by crystallization by cooling.
Woo Seob Shin, Cheol Hee Lim
Filed: 1 Jul 19
Utility
Processes for Preparing (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE or a Salt Thereof and Processes for Preparing Tofacitinib Using the Same
12 May 22
Provided are a novel process for preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine or a salt thereof, which is an intermediate useful for the preparation of tofacitinib, an intermediate used in the process, i.e., isopropanol solvate of methyl ((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)carbamate dibenzoyl-L-tartrate, an intermediate, having excellent stability, useful for the preparation of tofacitinib, i.e., (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine acetate, and a process for preparing tofacitinib or a pharmaceutically acceptable salt thereof.
Sang-Ho OH, Doo-Byung LEE, Kyoung-Chan KWON, Sang-Won KIM, Hyo-Ick HWANG, Kyeong-Sill LEE, Ik-Su JO, Ji-Hye CHOI, Sung-Hee CHO, Su-Young LEE
Filed: 3 Apr 20
Utility
Process for preparing aminopyrimidine derivatives
29 Mar 22
The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors.
Sang-Ho Oh, Ja-Heouk Khoo, Jong-Chul Lim, Seong-Ran Lee, Hyun Ju, Woo-Seob Shin, Dae-Gyu Park, Su-Min Park, Yoon-Ah Hwang
Filed: 8 Dec 20
Utility
TRIAZOLOPYRIDIN-3-ONES or Their Salts and Pharmaceutical Compositions Comprising the Same
27 Jan 22
The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof.
Tae Dong HAN, Hee Jae TAK, Eun Kyung KIM, Dong Hoon KIM, Su Bin CHOI, Sol PARK, Hyun Ho CHOI, Tae Wang KIM, Mi Kyeong JU, Na Ry HA
Filed: 6 Jul 21
Utility
Long-acting FGF21 Fusion Proteins and Pharmaceutical Composition Comprising Same
6 Jan 22
A fusion protein comprises an FGF21 mutant protein and an Fc region of an immunoglobulin.
Jun Hwan KIM, Seyoung LIM, Minji SEO, Hyun Ho CHOI, Dohoon KIM, Mi Kyeong JU, Ju-Young PARK, Byung Hyun CHOI, Jun Kyung LEE, Jong Gyun KIM, Su Youn NAM
Filed: 17 Sep 21
Utility
Dual Function Proteins Comprising FGF21 Mutant Protein and Pharmaceutical Composition Comprising Same
6 Jan 22
A dual function protein is disclosed.
Jun Hwan KIM, Seyoung LIM, Minji SEO, Hyun Ho CHOI, Dohoon KIM, Mi Kyeong JU, Ju-Young PARK, Seul Gi KIM, Sangmyoun LIM, Jong Gyun KIM, Su Youn NAM
Filed: 17 Sep 21
Utility
Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
14 Dec 21
The present invention provides intermediates useful for the synthesis of an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors; and processes for preparing the same.
Sang-Ho Oh, Ja-Heouk Khoo, Jong-Chul Lim, Doo-Byung Lee, Jung-Ae Lee, Jun-Sup Lee, Hyun Ju, Woo-Seob Shin, Sang-Seol Jeon
Filed: 25 Jul 18
Utility
Pharmaceutical composition containing FGF21 mutant fusion protein and method for treating hepatitis, hepatic fibrosis, and hepatic cirrhosis
23 Nov 21
A fusion protein containing a biologically active protein and an FGF21 mutant protein, a pharmaceutical composition containing the fusion protein, and their uses are disclosed.
Han Na Hong, Jun Hwan Kim, Hyun Ho Choi, Dohoon Kim, Taewang Kim, Se Woong Oh, Moo Young Song, Jong Gyun Kim
Filed: 10 Nov 17
Utility
3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
9 Nov 21
The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof.
Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Eui Chul Lee, Sol Park, Hyok Jun Cho, Cheol Hee Lim, So Young Kim, Hyun Ho Choi, Da Na Jeong, Na Yeon Yang, Na Ry Ha
Filed: 12 Dec 19
Utility
Pharmaceutical Composition for Oral Administration Comprising Aminopyrimidine Derivative or Its Salt
21 Oct 21
The present disclosure provides a pharmaceutical composition for oral administration comprising: N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pirimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide (Lazertinib) or its pharmaceutically acceptable salt as an active ingredient; and a combination of microcrystalline cellulose and mannitol as a diluent.
Seongkyu KIM, Deokkyu LEE, Soo-Won KIM, Jun-Mo YANG, Yoong-Sik PARK
Filed: 17 Oct 19